Revised Perspective on the AJCC Staging System for Medullary Thyroid Cancer: A Study of Two Nationwide Cohorts
Search for other papers by Cenkai Shen in
Current site
Google Scholar
PubMed
Search for other papers by Yuxin Du in
Current site
Google Scholar
PubMed
Search for other papers by Shiyu Xiang in
Current site
Google Scholar
PubMed
Search for other papers by Zimeng Li in
Current site
Google Scholar
PubMed
Search for other papers by Chuqiao Liu in
Current site
Google Scholar
PubMed
Search for other papers by Zhiyan Liu in
Current site
Google Scholar
PubMed
Search for other papers by Yijun Wu in
Current site
Google Scholar
PubMed
Search for other papers by Liang Guo in
Current site
Google Scholar
PubMed
Search for other papers by Yan Zhang in
Current site
Google Scholar
PubMed
Search for other papers by Hao Zhang in
Current site
Google Scholar
PubMed
Search for other papers by Chuang Chen in
Current site
Google Scholar
PubMed
Search for other papers by Min Yin in
Current site
Google Scholar
PubMed
Search for other papers by Haitao Tang in
Current site
Google Scholar
PubMed
Search for other papers by Qinghai Ji in
Current site
Google Scholar
PubMed
Search for other papers by Wenjun Wei in
Current site
Google Scholar
PubMed
Search for other papers by Xiao Shi in
Current site
Google Scholar
PubMed
Search for other papers by Yu Wang in
Current site
Google Scholar
PubMed
Background: The current AJCC TNM staging system for medullary thyroid cancer (MTC) is largely adapted from criteria for differentiated thyroid cancer, which may not fully capture MTC-specific prognostic factors. This study aimed to evaluate the prognostic significance of upper mediastinal lymph node metastasis (LNM) and propose corresponding modifications to the N category and staging system to improve their applicability for MTC. Methods: We conducted a population-based, retrospective study enrolling patients with MTC from 19 Chinese referral centers. Demographics and pathologic characteristics were collected, and patients were categorized into 4 LNM subgroups: no LNM, central cervical LNM, lateral cervical LNM, and upper mediastinal (level VII) LNM. We assessed their prognostic significance using Kaplan-Meier survival curves and Cox regression analysis. Recursive partitioning analysis was then applied to regroup patients with similar overall survival (OS). To validate our findings, we analyzed an independent cohort from the SEER database. Results: Our multicenter cohort included 827 patients with initially treated MTC, of whom 438 (53.0%) were female, with a median age of 50 years (IQR, 40–59). Upper mediastinal (level VII) LNM was present in 12.6% of patients and was significantly associated with worse OS, structural recurrence-free survival, and biochemical response compared with other LNM sites (all P<.05). Based on these findings, we proposed up-classifying level VII metastases from N1a to a new category, N1c, while keeping the T and M definitions unchanged. We then regrouped 4 TNM stages: stage I (T1–2N0–1aM0), stage II (T1–3N1bM0, T3N0–1aM0), stage III (T4N0–1bM0, T1–3N1cM0), and stage IV (T4N1cM0, T1–4N0–1cM1). Our modified staging system demonstrated superior prognostic discrimination and predictive power compared with the current AJCC TNM system, both in our multicenter cohort and the SEER validation cohort. Conclusions: For the first time, we identified the upper mediastinum as the most critical site for regional LNM in MTC. Our proposed adjustments to the N category and TNM staging system could provide better risk stratification for patients with MTC, potentially guiding improved clinical management and treatment strategies.
Submitted July 3, 2024; final revision received October 16, 2024; accepted for publication December 3, 2024. Published online March 13, 2025.
C. Shen, Y. Du, S. Xiang, and Z. Li contributed equally.
Author contributions: Conception & design: Wei, Shi, Y. Wang. Provision of study materials & patients: Z.Y. Liu, Wu, Guo, H. Zhang, Wang. Data analysis & interpretation: Shen, Du, Xiang, Z. Li. Methodology: Shen, Xiang, Shi. Administrative support: Ji, Y. Wang. Writing—original draft: Shen, Du. Supervision: All authors. Writing—review & editing: Shen, Xiang, Z. Li, C. Liu, Y. Zhang, Yin, Tang, Shi.
Data availability: Deidentified patient data will be available upon reasonable request to the corresponding author via email, after institutional approval and with a signed data access agreement.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: This work was supported by funding from the National Natural Science Foundation of China (82072951, Y. Wang; 82373008 and 82002830, X. Shi), Shanghai Hospital Development Center (SHDC2020CR6003-001, Y. Wang), and Science and Technology Commission of Shanghai Municipality (22Y21900100 and 23DZ2305600, Y. Wang; 23ZR1412000, X. Shi; 24ZR1413000, C. Shen).
Supplementary material: Supplementary material associated with this article is available online at https://doi.org/10.6004/jnccn.2024.7095. The supplementary material has been supplied by the author(s) and appears in its originally submitted form. It has not been edited or vetted by JNCCN. All contents and opinions are solely those of the author. Any comments or questions related to the supplementary materials should be directed to the corresponding author.
Supplementary Materials
- Supplemental Materials (PDF 0.98 MB)
© 2019-2024 National Comprehensive Cancer Network